Scott A Laurie

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. doi request reprint A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group
    Scott A Laurie
    Department of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa ON K1H 8L6, Canada
    Cancer 116:362-8. 2010
  2. doi request reprint Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
    Scott A Laurie
    Ottawa Hospital Cancer Centre, Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
    Lancet Oncol 12:815-24. 2011
  3. ncbi request reprint A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
    Scott A Laurie
    Division of Medical Oncology and Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
    Clin Cancer Res 12:2555-62. 2006
  4. doi request reprint Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
    Scott A Laurie
    The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa ON K1H 8L6, Canada
    J Clin Oncol 26:1871-8. 2008
  5. ncbi request reprint Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer
    Scott A Laurie
    Division of Medical Oncology, The Ottawa Hospital Regional Cancer Centre and the University of Ottawa, Ottawa, Ontario, Canada
    J Thorac Oncol 1:146-51. 2006
  6. doi request reprint Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
    Glenwood D Goss
    FCP SA, FRCPC, The Ottawa Hospital Cancer Centre, 501 Smyth Rd, Ottawa ON K1H 8L6, Canada
    J Clin Oncol 28:49-55. 2010
  7. doi request reprint A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies
    Laura Q M Chow
    Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
    Cancer Chemother Pharmacol 71:1273-85. 2013
  8. doi request reprint Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer
    Sandra Froeschl
    Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Canada
    J Thorac Oncol 3:163-9. 2008
  9. ncbi request reprint Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis
    Jair Bar
    The Ottawa Hospital Cancer Centre, Ottawa, Canada
    Clin Lung Cancer 14:200-4. 2013
  10. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009

Detail Information

Publications23

  1. doi request reprint A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group
    Scott A Laurie
    Department of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa ON K1H 8L6, Canada
    Cancer 116:362-8. 2010
    ..This phase 2 trial evaluated the combination of gemcitabine with cisplatin (carboplatin in those with protocol-defined contraindications to cisplatin)...
  2. doi request reprint Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
    Scott A Laurie
    Ottawa Hospital Cancer Centre, Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
    Lancet Oncol 12:815-24. 2011
    ..34 trials involving 441 patients are included. We give evidence-based recommendations for management of ACC with chemotherapy, along with considerations for the design of future clinical trials in this disease...
  3. ncbi request reprint A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
    Scott A Laurie
    Division of Medical Oncology and Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
    Clin Cancer Res 12:2555-62. 2006
    ..This study tested the hypothesis that two-step desensitization, using two dose increments before high repeat doses, would be well tolerated...
  4. doi request reprint Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
    Scott A Laurie
    The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa ON K1H 8L6, Canada
    J Clin Oncol 26:1871-8. 2008
    ..Doses of up to 45 mg/d of AZD2171 are tolerable when administered alone. This study evaluated escalating doses of AZD2171 in combination with standard chemotherapy in patients with advanced non-small-cell lung cancer...
  5. ncbi request reprint Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer
    Scott A Laurie
    Division of Medical Oncology, The Ottawa Hospital Regional Cancer Centre and the University of Ottawa, Ottawa, Ontario, Canada
    J Thorac Oncol 1:146-51. 2006
    ..The objective of this study was to explore the relationship between anemia and treatment outcomes in patients with LD-SCLC treated with CCRT...
  6. doi request reprint Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
    Glenwood D Goss
    FCP SA, FRCPC, The Ottawa Hospital Cancer Centre, 501 Smyth Rd, Ottawa ON K1H 8L6, Canada
    J Clin Oncol 28:49-55. 2010
    ....
  7. doi request reprint A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies
    Laura Q M Chow
    Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
    Cancer Chemother Pharmacol 71:1273-85. 2013
    ..Secondary endpoints included safety, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and preliminary efficacy...
  8. doi request reprint Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer
    Sandra Froeschl
    Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Canada
    J Thorac Oncol 3:163-9. 2008
    ..The optimal role of additional chemotherapy at the time of progression is controversial. We reviewed the experience of all patients over a 5-year period with ED SCLC to describe outcomes of second-line chemotherapy...
  9. ncbi request reprint Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis
    Jair Bar
    The Ottawa Hospital Cancer Centre, Ottawa, Canada
    Clin Lung Cancer 14:200-4. 2013
    ..We retrospectively collected data from patients treated this way to assess their outcomes and to identify prognostic factors...
  10. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009
    ..This study determined the recommended phase II dose (RP2D) of docetaxel plus GTI-2040, toxicity, and response rate in advanced non-small cell lung cancer (NSCLC)...
  11. doi request reprint Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status
    Glenwood Goss
    Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Rd, Ottawa, Ontario K1H 8L6, Canada
    J Clin Oncol 27:2253-60. 2009
    ..To compare gefitinib with placebo in chemotherapy naïve patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status...
  12. doi request reprint NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer
    Peter M Ellis
    Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton Ontario, Canada Medical Oncology Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada and NCIC CTG Queens University, Kingston, Ontario, Canada
    J Thorac Oncol 9:410-3. 2014
    ..Dalotuzumab can be combined at full dose with standard doses of cisplatin and etoposide. The observed toxicities are consistent with that expected from cisplatin and etoposide except for hyperglycemia, which seems to be dose dependent...
  13. doi request reprint A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer
    Peter M Ellis
    Juravinski Cancer Centre, Hamilton, Ontario, Canada
    Clin Lung Cancer 14:19-27. 2013
    ....
  14. doi request reprint Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group
    Scott A Laurie
    The NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    J Thorac Oncol 6:1950-4. 2011
    ..After the failure of standard first-line cisplatin/antifolate chemotherapy, there is no accepted treatment. The vascular endothelial growth factor pathway may be a relevant therapeutic target in MPM...
  15. ncbi request reprint Systemic therapy in the palliative management of advanced salivary gland cancers
    Scott A Laurie
    Ottawa Hospital Regional Cancer Centre, The University of Ottawa, Ottawa, Canada
    J Clin Oncol 24:2673-8. 2006
    ..There is a need for a determined, coordinated effort to conduct high-quality clinical trials in patients with these rare cancers...
  16. doi request reprint A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium
    Scott A Laurie
    The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario Electronic address
    Clin Lung Cancer 15:52-7. 2014
    ..The activity of saracatinib, an orally available inhibitor of src kinases, was evaluated in patients with advanced, platinum-pretreated NSCLC...
  17. doi request reprint Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer
    Scott A Laurie
    Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada
    J Clin Oncol 31:1061-9. 2013
    ..Several strategies to increase the efficacy of these inhibitors in wild-type NSCLC are the subject of ongoing investigations...
  18. ncbi request reprint Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer
    Kent Russell
    Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Clin Lung Cancer 15:237-43. 2014
    ..A retrospective analysis was performed to investigate factors influencing outcomes in these patients...
  19. ncbi request reprint Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer
    Scott A Laurie
    Ottowa Regional Cancer Centre, Ottawa, ON, Canada
    Lung Cancer 43:223-40. 2004
    ....
  20. ncbi request reprint Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients
    Jean Louis Pujol
    Montpellier Academic Hospital, Montpellier, France
    J Thorac Oncol 1:417-24. 2006
    ..This study does not support the concurrent administration of gefitinib and vinorelbine, with or without cisplatin, as a valid treatment for advanced NSCLC...
  21. ncbi request reprint Phase I study of green tea extract in patients with advanced lung cancer
    Scott A Laurie
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10126, USA
    Cancer Chemother Pharmacol 55:33-8. 2005
    ..This trial was designed to determine the maximum tolerated dose (MTD) of green tea extract (GTE) in patients with advanced lung cancer...
  22. ncbi request reprint Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
    Robert M Lorence
    Wellstat Biologics Corporation, 930 Clopper Road, Gaithersburg, MD 20878, USA
    Curr Opin Mol Ther 5:618-24. 2003
    ..Phase II studies are planned...
  23. ncbi request reprint The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease
    Scott A Laurie
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 95:119-26. 2002
    ..The objective of this study was to document the natural history of second lung carcinomas, common second tumors that arise in survivors of Hodgkin disease (HD)...